Abstract

Objective: The goal of this study was the evaluate demographics, tumor locations and resection rates of patients with diffus gliomas who were operated at our center.

Methods: Retrospective research was conducted on adult-type diffuse gliomas operated between January 2018 and December 2024 at a tertiary care center. Patient demographics, tumor localizations, extent of surgical resections and re-operations were assessed. The extent of resections were classified under gross total resection (GTR), subtotal resection (STR) or biopsy.

Results: 80 patients were included in the study consisting of 37 females and 43 males. The mean age was 55.9 for females and 48.6 for males. The most common location for tumors were frontal lobe (%45), followed by temporal lobe (%31.2). GTR was achieved in 29 glioblastoma cases and STR in 11, for oligodendrogliomas 10 GTRs and 3 STRs were achieved and among astrocytomas 9 GTRs and 5 STRs were achieved. 11 patients were re-operated due to reccurrence. Observed resection rates were consistent with reported rates in the literature. Notably, maximal safe resection rate in patients younger than 40 years was associated with prolonged survival.

Conclusion: Achieving maximal safe resection should be considered as a primary goal for diffuse glioma surgeries in order to improve both survival and the quality of life. Resection rates obtained at our center were comparable to those reported in other studies, with a more pronounced survival benefit for younger patients.

Keywords: diffuse glial tumors, maximal safe resection, surgical strategy

References

  1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23: 1231-1251. https://doi.org/10.1093/neuonc/noab106
  2. Kessler T, Ito J, Wick W, Wick A. Conventional and emerging treatments of astrocytomas and oligodendrogliomas. J Neurooncol 2023; 162: 471-478. https://doi.org/10.1007/s11060-022-04216-z
  3. Sanai N, Berger MS. Operative techniques for gliomas and the value of extent of resection. Neurotherapeutics 2009; 6: 478-486. https://doi.org/10.1016/j.nurt.2009.04.005
  4. Brown TJ, Brennan MC, Li M, et al. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol 2016; 2: 1460-1469. https://doi.org/10.1001/jamaoncol.2016.1373
  5. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011; 115: 3-8. https://doi.org/10.3171/2011.2.jns10998
  6. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008; 26: 1338-1345. https://doi.org/10.1200/JCO.2007.13.9337
  7. Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017; 18: e315-e329. https://doi.org/10.1016/S1470-2045(17)30194-8
  8. Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg 2012; 117: 851-859. https://doi.org/10.3171/2012.8.JNS12234
  9. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012; 117: 1032-1038. https://doi.org/10.3171/2012.9.JNS12504
  10. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401. https://doi.org/10.1016/S1470-2045(06)70665-9
  11. Koc K, Anik I, Cabuk B, Ceylan S. Fluorescein sodium-guided surgery in glioblastoma multiforme: a prospective evaluation. Br J Neurosurg 2008; 22: 99-103. https://doi.org/10.1080/02688690701765524
  12. Bello L, Gallucci M, Fava M, et al. Intraoperative subcortical language tract mapping guides surgical removal of gliomas involving speech areas. Neurosurgery 2007; 60: 67-80; discussion 80-2. https://doi.org/10.1227/01.NEU.0000249206.58601.DE
  13. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31: 337-343. https://doi.org/10.1200/JCO.2012.43.2674

Copyright and license

Copyright © 2025 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Karataş M, Koca A, Ergen A, Çaklılı M, Anık İ. Surgical strategy in diffuse glial tumor. Sinir Sistemi Cerrahisi Derg 2025;10(2):59-65. https://doi.org/10.54306/SSCD.2025.220